Want to join the conversation?
$IDRA expects initiating a Phase 2 clinical trial of IMO-8400 in dermatomyositis in 4Q15. The company may enroll approx. 48 patients in the trial which it expects to conduct at approx. 20 clinical sites. As of Sept. 30, 2015, $IDRA had an accumulated deficit of $488MM and anticipates incurring substantial operating losses in future periods.
$DB is going to cut off services for about 3,400 clients in equities trading.
$F stock slid more than 2% after the company issued two safety recalls involving more than 650,000 Ford Fusion and Lincoln MKZ model cars.
The new CEO of $SBUX, Kevin Johnson, has some pretty large shoes to fill but there are many who have good faith in his ability to do so.
$TSLA opening a showroom in Michigan. A bold move !!